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Background: Endothelial progenitor cells (EPC) promote angiogenesis and vascular repair. Though reduced EPC
levels have been shown in rheumatoid arthritis, no study has so far evaluated EPCs in children with juvenile
idiopathic arthritis (JIA). We aimed to study circulating EPCs in children with JIA, their relation to disease activity,
and effects of anti TNF-α treatment.
Methods: Circulating EPCs were quantified by flow cytometry based on CD34, CD133 and KDR expression in
peripheral blood of 22 patients with oligoarticular JIA and 29 age-matched controls. EPCs were re-assessed in
children with methotrexate-resistant oligo-extended JIA before and up to 12 month after initiation of anti-TNF-alpha
therapy. Plasma concentrations of inflammatory and EPC-regulating factors were measured using a multiplex array.
Confocal immunofluorescence was used to demonstrate EPCs in synovial tissues.
Results: Children with active JIA showed a significant reduction of relative and absolute counts of circulating
progenitor cells and EPCs compared to age-matched healthy controls. CD34+ cell levels were modestly and
inversely correlated to disease activity. A strong inverse correlation was found between serum TNF-α and EPC
levels. In 8 patients treated with anti TNF-α agents, the number of EPCs rose to values similar to healthy controls.
CD34+KDR+ EPCs were found in the synovial tissue of JIA children, but not in control.
Conclusions: Children with JIA have reduced levels of the vasculoprotective and proangiogenic EPCs. While EPCs
may contribute to synovial tissue remodelling, EPC pauperization may indicate an excess cardiovascular risk if
projected later in life.
Keywords: Stem cells, Cardiovascular, Endothelium, AngiogenesisBackground
Juvenile Idiopathic Arthritis (JIA) is a heterogeneous
condition including all forms of chronic arthritis of
unknown origin with onset before the age of 16 and is
currently divided into different subgroups according to
the clinical features at onset [1]. JIA is characterised by
chronic inflammation of single or multiple joints leading
to synovial tissue hyperplasia, cartilage destruction and
bone erosion [2]. This process results from the prolifera-
tion of synoviocytes and the recruitment of activated* Correspondence: gianpaolo.fadini@unipd.it
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unless otherwise stated.inflammatory cells from the peripheral circulation [3,4].
One important aspect of synovial hyperplasia is the
formation of new blood vessels, or angiogenesis, which
increases the homing capacity of inflammatory cells to
the synovial tissue and fluid [4-6].
Endothelial progenitor cells (EPCs) are bone marrow
(BM) derived cells involved in the processes of angiogen-
esis and endothelial repair [7]. EPCs are part of a larger
population of circulating progenitor cells (CPCs), such
as the hematopoietic CD34+ population, which are
per se involved in angiogenesis [8]. Circulating EPCs
and CPCs are reduced in virtually all clinical condi-
tions associated with increased cardiovascular risk, such
that their levels in the bloodstream are now consideredThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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ture cardiovascular disease [7]. EPCs are also affected by
inflammatory diseases, with a possible early rise driven
by acute inflammation, followed by absolute depletion in
the chronic phases [9]. Several reports indicate that EPCs
and CPCs are quantitatively and qualitatively affected in
adults with rheumatoid arthritis (RA) [10], systemic
lupus erythematosus [11] and systemic sclerosis [12],
possibly reflecting impaired angiogenesis and/or in-
creased cardiovascular risk. However, to the best of our
knowledge, no study has so far analysed EPCs and CPCs
in the setting of JIA.
Therefore, aim of this study was to evaluate the circu-
lating levels of CPC and EPC in children with JIA, exam-
ine whether they correlate with clinical data, and
whether they are influenced by medical treatment, in
particular with anti TNF-α agents.
Methods
Patients
Peripheral blood samples from consecutive patients ful-
filling the revised criteria for JIA, according to the ILAR
(International League of Associations for Rheumatology)
Durban criteria [1] and managed at the Paediatric
Rheumatology Unit of Padova University were studied.
Peripheral blood samples were drawn for the determin-
ation of EPCs, CPCs, inflammatory markers and pro-
genitor cell mobilizing factors. At the time of blood
sample collection, all included patients had persistently
active disease: some of them were undergoing intraarti-
cular corticosteroid injection, other patients with metho-
trexate (MTX)-resistant oligo-extended JIA were starting
anti-TNF-α treatment. In these patients, blood samples
were collected 3 and 6 months after initiation of the anti
TNF-α agent.
The following clinical data were collected: age at onset
of JIA, disease duration, concomitant medications, over-
all assessment of disease activity by the physician’s visual
analogue scale (VAS) (range 0–100 mm), number of ac-
tive joints (joints with swelling not caused by deformity,
or joints with limited motion, and with pain, tenderness,
or both), laboratory markers of inflammation, including
erythrocyte sedimentation rate (ESR) and C-reactive pro-
tein (CRP) with normal value up to 25 mm/h and up to
6 mg/L, respectively, according to our laboratory standard.
Age- and sex-matched healthy subjects were recruited
from the service of Laboratory Medicine used as con-
trols. The study was approved by the University Hospital
of Padova and consent was obtained from the parents of
all the children taking part in this study.
Quantification of EPC in peripheral blood by flow cytometry
Progenitor cells in whole peripheral blood were quantified
based on the expression of surface antigens with direct3-color analysis, as described before [13], using fluores-
cein isothiocyanate (FITC)-conjugated, phycoerythrin
(PE)-conjugated and allophycocyanin (APC)-conjugated
monoclonal antibodies (mAbs) by flow cytometry
(FACSCalibur; Becton, Dickinson and Company,
Franklin Lakes, NJ, USA). Briefly, before staining with
specific monoclonal antibodies, cells were treated with
fetal calf serum for 10 minutes and then the samples
were washed with buffer containing phosphate-buffered
saline and 0.5% bovine albumin. Then, 150 μl of APC-
conjugated anti-human CD133 mAb (Miltenyi Biotec,
Bergisch Gladbach, Germany) and 10 μl of PE-
conjugated anti-human KDR mAb (R&D Systems Inc.,
Minneapolis) followed by incubation at 4°C for 30 mi-
nutes. Unlabeled cells or anti-isotype antibody served as
a control. The frequency of peripheral blood cells positive
for the above reagents was determined by a two-
dimensional side scattered-fluorescence dot plot analysis
of the samples, after appropriate gating. After morpho-
logical gating to exclude granulocyte and cell debris, we
gated CD34+ peripheral blood cells and then examined
the resulting population for dual and triple expression of
KDR and CD133. CPCs were defined as CD34+, CD133+
or CD34+CD133+ cells. Circulating EPCs were defined as
CD34+KDR+, CD133+KDR+ or CD133+CD34+KDR+
cells. For each analysis, 5 x 105 cells were acquired
and scored using a FACS-calibur analyzer (Becton,
Dickinson and Company). Data were processed using
the Macintosh CELLQuest software program (Becton,
Dickinson and Company). The same trained operator, who
was blind to the clinical status of the patients, performed
all the tests. Data are expressed as cells/106 events or as
cells/ml, by multiplying by white blood cell count.
Determination of inflammatory mediators and progenitor
cell mobilising factors
Plasma concentrations of IL-1β, IL-1ra, IL-6, bFGF,
G-CSF, PDGF-bb, TNF-α and VEGF were measured
using a customized multiplex suspension array (BioRad
Laboratories, Milan, Italy) according to the manufac-
turer’s instructions. This assay allows the simultaneous
detection of multiple molecules in a single well on
96-well microplate, using specific antibody-coupled
fluorescently dyed beads in a sandwich immunoassay.
White blood cells, ESR and CRP were determined on
an automated modular Roche Cobas Analyzer.
Confocal microscopy
Synovial tissue was obtained at time of arthroscopic
synovectomy in 3 patients with oligoarticular-onset
JIA and in 1 subject with non-inflammatory disease
(hypermobile joint), after informed consent was obtained
from the parents. In JIA, the procedure was performed
for clinical indication in the presence of persistently
Table 1 Clinical characteristics of patients included in
the study
Clinical characteristic Oligo-extended Oligoarticular
No. 13 9
Age mean (range), years 10.0 (3.0-21.6) 8.0 (4.4-14.3)
Disease duration, years 5.8 (0.4-17.4) 2.1 (0.2-13.3)*
ESR mean (range), mm/h 39.8 (10–101) 35.6 (14.0-90.0)
CRP mean (range), mg/L 23.5 (3.3-72.0) 9.4 (3.0-30.6)*
VAS mean (range), mm 7.5 (2.0-9.7) 7.2 (4.0-9.0)
No. of active joints 3.9 (1–13) 2.3 (1–5)*
Previous treatment None (3 pts)
Methotrexate (MTX, 4 pts)
Naproxen (NPX, 2 pts)
MTX/NPX (3 pts)
MTX/prednison (2 pts) None (3 pts)
Naproxen (6 pts)
*p < 0.05.
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inflammatory therapy or to intraarticular corticosteroid
injections. Confocal microscopy was used to confirm the
co-expression of CD34 and KDR (VEGFR2) in synovial
tissue cells, indicating locally homed EPCs. Paraffin sec-
tions were prepared for immunofluorescent labelling.
Briefly, primary antibodies against CD34 (ready to use,
Delta) and VEGFR2 (1:200 Santa Cruz) and secondary
antibodies (goat anti-mouse IgG and goat anti-mouse
IgG) conjugated with Cy3 and Cy2 (Sigma) were used,
respectively. TO-PRO 3 far red fluorescent probe
(Molecular Probes, Invitrogen) was used to label nuclei.
Double labelling using both antibodies on the same sec-
tion was performed. Primary and secondary antibodies
were incubated for 1 h at room temperature. Slides were
stored at 4°C and analysed within 24 h. As a negative
control, the primary antibody was omitted. Immuno-
fluorescence was evaluated with a confocal microscopy
(Leica TCS SL, Heidelberg, Germany) by using 488, 543
and 642 nm excitation. Images were analyzed using
Adobe Photoshop 7.0.
Statistical analysis
Normal distribution of variables was assessed using
the Kolmogorov-Smirnov test. Normal variables are
expressed as mean ± standard error, while non-normal
variables are expressed as median (interquartile range,
IQR). Differences between normal continuous variables
were assessed using unpaired two-tail Student’s t test,
while the Mann–Whitney test was used for non normal
continuous variables. The chi square test was used to
compare categorical variables between two groups. Dif-
ferences in variables assessed before and after anti-TNF
therapy were assayed using paired two-tail Student’s
t test the Wilkoxon rank test. Linear correlations were
evaluated by Pearson’s r coefficient. Statistical signifi-
cance was accepted at p < 0.05.
Results
Twenty-two JIA patients were included in the study, all
having a history of oligoarticular onset, with 9 showing
persistently oligoarticular course and 13 with extension
to polyarticular course (oligo-extended JIA). At the time
of blood sampling, 14 patients underwent intraarticular
steroid injection and 8 patients with MTX-resistant dis-
ease were started on anti TNF-α agents (6 etanercept
and 2 infliximab). The clinical characteristics of the pa-
tients are summarized in Table 1. Twenty nine control
subjects were included and were aged 8.6 ± 1.0 years
(range 2–15 years), 44% males, and were free from any
acute and chronic disease.
Children with active JIA showed significantly lower
levels of multiple CPC and EPC subtypes in periph-
eral blood compared to age-matched healthy controls.Specifically, significant reductions in relative cell counts
were detected for the total CD34+ cell population
(−47%), CD133+ cells (−30%), CD34+KDR+ cells (−68%)
and CD34+133+KDR+ (−71%), while there were non-
significant trend reductions in CD34+CD133+ and
CD133+KDR+ cells (Figure 1A). Absolute CD34+ and
CD34+KDR+ cell counts were also reduced in JIA as
compared to control subjects (Figure 1B).
Among all clinical characteristics, we only found a sig-
nificant negative correlation between CD34+ cell levels
and the physician’s visual analogue scale (Figure 2),
though this was mainly attributable to 3 patients with
low disease activity. There was no association between
progenitor cells and the clinical subtype (persistent oli-
goarticular or extended oligoarticular), disease duration,
and ongoing treatment regimens with NSAIDs and
MTX.
JIA children, compared to controls, showed significantly
higher concentrations of plasma TNF-α (95.9 ± 46.1 versus
22.7 ± 3.8 pg/mL; p = 0.002) and IL-6 (19.3 ± 3.2 versus
11.8 ± 1.8 pg/mL; p = 0.04), while there were no dif-
ferences in IL-1β, IL-1ra and progenitor cell mobiliz-
ing factors (bFGF, G-CSF, PDGF-bb, VEGF and SCF).
Within the JIA group, there were negative correlations
between TNF-α levels and the CD34+KDR+ (r = −0.79;
p < 0.001) and CD34+133+KDR+ (r = −0.52; p = 0.004)
EPC phenotypes.
In a group of 8 children with persistently active disease
despite treatment with MTX, the initiation of anti TNF-
α agents was followed by a significant increase in CPC
and EPC, at both 3 and 6 months after the start of treat-
ment. Consistently, we found significant clinical im-
provements in terms of ESR, CRP, VAS and number of
Figure 1 Progenitor cell phenotypes in JIA compared to control (CTRL) children. Cell counts are expressed, on different scales, as relative
to one million total cytometric events in (A) and as absolute concentration in (B). *p < 0.05 versus CTRL subjects. Generic CPCs include
CD34+, CD133+, CD34+CD133+ cells, whereas endothelial committed progenitor cells (EPCs) include CD34+KDR+, CD133+KDR+,
CD34+CD133+KDR+ cells.
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Figure 2 Correlation between CD34+ cells and disease activity. A
significant inverse linear correlation was detected between total
CD34+ cells and the physician’s visual analogue scale.
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blood sampling at 12 months, the increase in EPC and
CPC appeared to be sustained over time.
To understand whether EPC might be involved in
intra-articular tissue remodelling in the setting of JIA,
we performed confocal microscopy imaging of synovial
tissue obtained from patients with oligoarticular-onset at
time of synoviectomy. In the synovial tissue, CD34
labeled blood vessels and rounded cells in the inter-
stitium, that appear to be either isolated or in clus-
ters. CD34+ rounded cells, but not CD34+ elongated
cells in blood vessels, were also brightly positive for
VEGFR2 (KDR). Therefore, these cells can be bona
fide defined as tissue-resident CD34+KDR+ EPCs, simi-
lar to circulating EPCs. A control non-inflammatory
synovial tissue was completely negative for EPC markers
(Figure 4).
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Figure 3 Effects of anti-TNF-alpha therapy on the levels of progenitor cell phenotypes and clinical severity. ESR, CRP, VAS and progenitor cell
phenotypes were measured at baseline and after 3 and 6 months in 8 children with persistently active JIA. In 3 individuals, a blood sample was
also performed at 12 months. *p < 0.05 versus baseline.
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In this study we show for the first time that, compared
to age-matched healthy children, subjects with active JIA
displayed a marked reduction of multiple CPC and EPC
phenotypes, while such defect was counteracted by anti
TNF-α therapy.
Reductions in EPC levels have been previously shown
in the setting of adult RA and other rheumatic diseases,
including systemic lupus erythematosus, systemic scler-
osis, and Behcet disease [9-13]. There are at least two
possible explanations for the reduced levels of pro-
angiogenic and endothelial-reparative cells in JIA. First,
chronic inflammation, by continuously challenging and
stressing the bone marrow, may progressively exhaust
progenitor cell reserve and/or mobilization capacity [14].
Impaired bone marrow function and pauperization of
EPC progenies have been demonstrated to account for
circulating EPC reduction in diabetes and cardiovascular
disease [15,16], but fewer data are available on bone
marrow niche structure and function in rheumatic
diseases. Padadaki et al. found reduced bone marrow
CD34+ cells and increased apoptosis, along with defectivestromal cell function, which might account for impaired
stem cell mobilization in RA patients [17]. Future studies
on this topic may be important to better understand the
systems biology of rheumatic diseases, as the bone marrow
is being recognized as a central housekeeper of multiple
organ and tissue regenerative potential.
Second, the existence of cells with a phenotype corre-
sponding to circulating EPCs (CD34+KDR+) in the syn-
ovial tissue of JIA patients suggests that EPCs can be
recruited from the bloodstream to the affected joints
and might therefore contribute to tissue remodeling and
formation of pannus, which is a highly vascularized
pathologic structure. The presence of CD34+KDR+ cells
was previously shown also in the synovial tissue of pa-
tients with RA and osteoarthritis [18], indicating that
this is not a specific finding in JIA. While the homing
hypothesis is supported by preclinical studies showing
recruitment of bone marrow-derived cells to sites of in-
flamed joints in experimental arthritis and by the obser-
vation that VEGF blockade in murine collagen-induced
arthritis (CIA) significantly reduces synovial inflam-
mation [19], it is unclear to what extent can EPC
Figure 4 Bona fide EPC labelling in synovial tissue of JIA patients. A representative confocal imaging analysis of synovial tissue from a JIA patient
(upper lane) and from a child who underwent surgical debridement for a non-inflammatory condition (lower lane). The staining for CD34 and
VEGFR-2 (KDR) shows double positive CD34+KDR+ cells (bona fide EPCs) in clusters or as isolated cells only in the JIA case, while the control was
completely negative. Note that, as expected, CD34 also labels microvessels, although at lower intensity compared to isolated EPCs.
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state circulating EPC levels. In addition, this mechan-
ism would not be common to other rheumatic diseases
characterized by unaffected (e.g. SLE) or even impaired
(SS) angiogenesis, yet in which circulating EPCs are simi-
larly reduced.
Whichever the cause of progenitor cell reduction, it
is remarkable that this occurs in JIA children at the
same extent as in adults with RA [20]. Generic CPC,
such as CD34+ cells, and EPCs are involved in angio-
genesis and endothelial repair [8,21]. Therefore, a
chronic shortage of these cells in JIA children may,
over the decades, translate into impaired vascular
homeostasis and promote cardiovascular disease later
in life [22]. The cardiovascular risk associated with RA
in adults is well established [23]. In the last years, there
is a growing interest in investigating whether children
with JIA may also have an increased cardiovascular risk,
as inflammation is a common driver in the pathogen-
esis of both arthritis and atherosclerosis, which starts
early in life [24]. For instance, children with JIA have
elevated levels of pro-inflammatory adhesion molecules
suggestive of endothelial activation and known to be as-
sociated with vascular dysfunction [25]. Moreover, sev-
eral studies exploring vascular function with blood
pressure, aortic stiffness and other surrogate markers of
CVD, such as carotid-intima media thickness (cIMT)
and brachial artery flow-mediated dilatation (FMD),suggest that patients with JIA may have vascular dys-
function [26,27].
On this basis, understanding the mechanisms driving
the pathological change in the vascular regenerative cap-
acity in JIA is of paramount importance. Herein, we
show that circulating EPC reduction was correlated to
increased plasma TNF-α concentrations. In vitro, TNF-α
was previously shown to reduce EPC generation and
survival, through the p38 mitogen associate protein kin-
ase pathway [28]. The negative role played by TNF-α in
reducing EPCs in JIA is substantiated by the finding that
EPCs were restored toward normal levels after initiation
of anti TNF-α therapy. Similar results have been ob-
tained in studies on adults with RA [20,29], but it should
be acknowledged that a definite demonstration that res-
toration of EPC levels is directly mediated by blocking
TNF-α signaling is still missing. Indeed, a generalized
improvement in the inflammatory milieu may also favor-
ably affect EPCs, independently of TNF-α. In addition,
one limitation this longitudinal observational study is
that the treatment was decided on clinical ground and
not randomly assigned.
Despite efforts made by several investigators for a
standardization of the exact EPC phenotype, no general
consensus is available [7]. Even the EUSTAR guidelines
do not provide a balanced view, as different aspects, ran-
ging from enrichment strategies to the choice of surface
biomarkers, are questionable [30]. While quantification
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remains the most accepted way of determining EPC
levels, the simultaneous analysis of several generic and
endothelial progenitor cell phenotypes can strengthen
the results. In fact, our study show that multiple pro-
genitor cell subtypes were reduced in JIA, clearly point-
ing to a generalized pauperization of regenerative cells.
Conclusions
We show for the first time that children with JIA have
significantly reduced levels of circulating cells involved
in endothelial repair and angiogenesis. This novel find-
ing, though observational, provides a clue to the worri-
some excess of cardiovascular risk in JIA children, which
can impact their life in adulthood. Reversibility of this
defect after anti TNF-α therapy is a remarkable observa-
tion that needs to be confirmed in controlled trials. The
effect on EPCs might be considered as a surrogate to assess
the favorable cardiovascular effects of TNF blocking.
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